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Abstract 30 
Protein glycation has been studied for over a century now and plays an important role in disease 31 
pathogenesis throughout the lifecycle. Strongly related to diabetic complications, glycation of 32 
haemoglobin has become the gold standard method for diabetes diagnosis and monitoring. It is 33 
however attracting attention in normoglycaemia as well lately. Longitudinal studies increasingly 34 
suggest a positive relationship between glycation and the risk of chronic diseases in 35 
normoglycaemic individuals, but the mechanisms behind this association remain unclear. The 36 
interaction between glycation and oxidative stress may be particularly relevant in the 37 
normoglycaemic context, as suggested by recent epidemiological and in-vitro evidence. In that 38 
context nutritional and lifestyle factors with an influence on redox status, such as smoking, fruit and 39 
vegetable and antioxidants consumption, may have the capacity to promote or inhibit glycation. 40 
However, experimental data from controlled trials are lacking the quality and rigor needed to reach 41 
firm conclusions. In this review, we discuss the importance of glycation for health through the 42 
lifecycle and focus on the importance of oxidative stress as a driver for glycation. The importance 43 
of nutrition to modulate glycation is discussed, based on the evidence available and 44 
recommendations towards higher quality future research are made. 45 
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 50 
The glycation reaction - historical background 51 
Glycation, also referred to as non-enzymatic browning or the Maillard reaction, has attracted 52 
scientific interest for nearly a century. Initiated by the non-enzymatic condensation of a reducing 53 
sugar (like glucose) with a protein, glycation is one of the most important forms of protein 54 
damage/loss, relevant to both medicine and food science. Named after the pioneer in the field, the 55 
Maillard reactions were described  in 1912(1) and systematically presented for the first time by  John 56 
E. Hodge in 1955(2). During the early years, glycation was studied in the context of food science, 57 
food processing and hence relative to health via nutritional intake. In 1977, a fraction of 58 
haemoglobin, HbA1c, was identified as a ketoamine (glycation product) and the concept of in-vivo 59 
protein glycation gradually became mainstream(3-5). HbA1c was proposed as a useful biomarker for 60 
diabetes monitoring(3; 4), and endogenously produced Advanced Glycation Endproducts (AGEs)  61 
have since attracted further scientific attention, beyond food chemistry, from fields including 62 
medical biochemistry and pathology. 63 
The importance of glycation for health 64 
Glycation and the AGE-RAGE axis  65 
The study of the role played by glycation in disease pathogenesis originally relied on measuring 66 
fructosamine levels in biological fluids, combined with the characterisation of endogenous AGEs in 67 
the circulation and tissues(6; 7). These measurements were related to glycaemia and the topic very 68 
much focused on diabetes(3-5).  69 
In hyperglycaemia (post-prandially or in non-controlled diabetes) and to a lesser extent in 70 
normoglycaemia, both circulatory proteins and proteins of the endothelium are exposed to (excess) 71 
glucose, leading to the slow formation of AGEs(8-11). During that process, glycation adducts are 72 
created on the protein molecule, as a function of glucose levels. Accumulation of glycation adducts 73 
on the protein promotes excessive cross-linking with other protein molecules, which, in the case of 74 
collagen for example, would inhibit the formation of an ordered and functional polymeric complex. 75 
Such changes could lead to the formation of a thick vascular wall with i) reduced elasticity and ii) a 76 
high affinity of collagen to bind other circulating proteins like IgG, albumin and lipoproteins like 77 
LDL(12-21). In turn, the immobilisation of proteins on the vascular wall will promote further 78 
glycation and cross-linking and will act as a signal for chemo-attraction of macrophages and 79 
monocytes, promoting inflammation and ‘foam’ cell formation in the endothelium(22-24).  80 
The discovery that AGEs can bind on cellular receptors and alter intracellular events was a 81 
breakthrough, linking glycation to signalling(25). Receptors like AGE-R1, AGE-R2, AGE-R3, 82 
MSRII, CD36, LOX-1 and the Receptor for AGEs (RAGE), the most characterised receptor(26), are 83 
multi-ligand cell-surface immunoglobulins, with the ability to initiate injury-like intracellular events, 84 
mainly expression of genes related with inflammation and oxidative stress(27-29).  Upon activation of 85 
RAGE, intracellular ROS levels are increased through up-regulation of NAD(P)H oxidase 86 
expression. This in turns leads to the activation of the Ras-MAP kinase pathway, ultimately up-87 
regulating NFκB and the production of inflammatory molecules (including TNF-a, VCAM-1, I-88 
CAM1 and IL-1beta). The up-regulation of NFκB also initiates a positive feedback loop that 89 
sensitises the cell (and hence the tissue) to AGEs by promoting RAGE production(24).  90 
Together accumulation of AGEs in tissues and AGE-RAGE interactions are the two main pathways 91 
of glycation involvement in disease pathogenesis. These two pathways are often acting 92 
simultaneously and their individual effects are hard to distinguish; hence they are commonly 93 
presented in the same context when discussing glycation related pathophysiology(12; 30-34).   94 
Glycation and health throughout the lifecycle 95 
Glycation is relevant to all stages in the lifecycle, including conception and early gestation. The 96 
reproductive tract is a known site for AGEs accumulation both in men(35) and women(36).  AGEs 97 
accumulation is followed by changes in the distribution of RAGE in reproductive tissues(37), and 98 
sRAGE (the soluble isoform of RAGE) in seminal/follicular fluid(38; 39), which may lead to lower 99 
sperm quality(38), lower likelihood of success following assisted reproduction(40; 41) and reduced 100 
embryonal quality and development(39; 41; 42). During the course of pregnancy, activation of the 101 
AGE-RAGE axis may be involved in the pathogenesis of preeclampsia(43-45). So far evidence on the 102 
involvement of AGEs and/or RAGE in fetal development are limited and based on animal studies.  103 
For example a study on transgenic mice showed that overexpression of RAGE was associated with 104 
impairments in alveolar morphogenesis. The degree of RAGE overexpression was related to the 105 
magnitude of the abnormality with homozygous mice having histological changes similar to human 106 
bronchopulmonary dysplasia. The study also found that this early life changes could lead to 107 
increased risk of ‘destructive’ emphysema(46). Glycation has also been proposed as a mechanism of 108 
ageing(47; 48). Evidence from animal models suggest that a diet low in AGEs (50% reduction in 109 
AGEs intake) was associated with amelioration of insulin resistance, lower AGEs accumulation 110 
(both indications of the ageing process) and ultimately increased lifespan compared to the 111 
controls(49). Similarly, mice on caloric restriction, a popular model of lifespan expansion in animal 112 
models, have lower levels of collagen cross-linking and lower levels of lens cataract, suggesting 113 
lower AGEs accumulation in the vitreous and the extracellular matrix(50; 51) as well as in the brain(52). 114 
In fact, mice fed high AGEs diets while on caloric restriction did not show any increase in their 115 
lifespan and the authors of the report suggested that lower AGEs intake may be one of the 116 
mechanisms behind the caloric restriction model(49; 53). An interesting observation linking the effect 117 
of AGEs in ageing and as early in life as in conception comes from a study showing the active 118 
involvement of AGEs accumulation in ovarian ageing and ovarian function in human subjects(54). 119 
 120 
HbA1c and risk of chronic diseases 121 
Even though the exact mechanisms of disease pathogenesis remain elusive, extensive evidence is 122 
available to associate glycation with disease risk.  Glycation has a particular relevance for age-123 
related diseases, including Alzheimer’s disease(55; 56), skin ageing(48) and cataract(47). These 124 
conditions are characterised by increased, possibly lifelong, deposition of AGEs in the affected 125 
tissue(57-59).  126 
As in-vivo glycation is believed to be mainly driven by plasma glucose concentrations, the most 127 
established relationship is between glycation and diabetes. HbA1c is the gold standard method for 128 
diabetes diagnosis and monitoring(60). According to the American Diabetes Association, individuals 129 
with HbA1c levels between 5.7-6.5 % are considered at high risk of developing diabetes. Those 130 
with HbA1c>6.5% are classified as having diabetes(61). Among patients with diabetes, higher 131 
HbA1c levels are associated with increased risk of retinopathy(62-66), neuropathy(67) and 132 
nephropathy(66).  133 
Glycation has recently attracted attention as a risk factor for normoglycaemic individuals. For the 134 
purpose of this paper, we conducted a systematic literature search to identify studies documenting 135 
the effect of increased glycation on the risk of non-communicable chronic diseases in 136 
normoglycaemic subjects. We identified 15 reports from 8 studies (European Prospective 137 
Investigation into Cancer and Nutrition-EPIC(68; 69), Atherosclerosis Risk in Communities study-138 
ARIC(70-73), Australian Diabetes, Obesity and Lifestlyle study-AusDiab(74), the Hoorn Study(75; 76), 139 
Framingham Offspring(77), Rancho Bernardo(78), Women’s Health Study-WHS(79-81) and National 140 
Survey of Cardiovascular Disorders 1990-NIPPON DATA90(82)) analysing data from a total of over 141 
63,000 participants, followed-up for 4-15 years.  The outcomes of interest were diabetes risk, 142 
cardiovascular disease (CVD), ischemic heart disease, stroke, coronary heart disease (CHD) and all-143 
cause and CVD mortality. Two reports focused on the association between glycation and cancer 144 
risk, especially colorectal(69) and breast cancer(80).  Overall, the studies showed a positive 145 
relationship between higher HbA1c and the risk of stroke and/or CVD and/or mortality ranging 146 
between 18-55% higher risks per 1% increase in HbA1c(68-74; 82) .  As far as cancer incidence is 147 
concerned, the results are still inconclusive. Data from the EPIC cohort suggest a 33% increase in 148 
the incidence of colorectal cancer per every 1% increase in HbA1c(69), but an analysis of the WHS 149 
data did not find any association between HbA1c and breast cancer risk(80). As the two cancer types 150 
differ significantly in aetiology, colorectal cancer has a strong dietary link(83) while breast cancer is 151 
mainly of genetic aetiology(84); more research is needed before any conclusion is reached.  152 
Oxidative stress and protein glycation in normoglycaemia 153 
As observed by Selvin et al(70), fasting glucose may fail to explain the positive relationship between 154 
HbA1c and CVD and/or mortality. Correction for classical risk factors (including smoking, 155 
dyslipidaemia, inflammation) explain the relationship better(75; 76; 79; 81), suggesting that a shared 156 
mechanism may drive the increase in HbA1c levels. Although indications and potential mechanisms 157 
are in place to suggest an active involvement of oxidative stress in protein glycation in 158 
normoglycaemia and hence the increase in the risk of chronic diseases, so far little evidence is 159 
available to support such a hypothesis. 160 
In our previous work, we hypothesised that oxidative stress could be this shared mechanism, which 161 
acts as a glycation driver in normoglycaemia.  162 
Using the Scottish Health Surveys (SHS) datasets 1993-2010, we have shown that, in individuals 163 
without diabetes and HbA1c levels lower than 6.5%,  age-sex adjusted HbA1c levels are positively 164 
correlated with smoking status, an association seen even among ex-smokers who used to smoke 165 
regularly(85). Smoking status was used as a proxy for oxidative stress and, in a similar way, fruit and 166 
vegetable intake was used as a proxy for antioxidant intake. Smoking was positively associated with 167 
HbA1c levels from as few as 10 cigaretes per day a finding consistent with previous reports (86; 87) 168 
(Figure1). The likelihood of having an HbA1c level within the prediabetes range (5.7-6.4%) was 169 
double among smokers compared to non- smokers; this was seen even with less than 10 cigarettes 170 
per day smoked. Interestingly, smoking cessation does not lead to complete reversal to the non-171 
smoking state, as former smokers were found to have lower HbA1c levels  than smokers but not as 172 
low as never smokers(86; 87). In a linear regression model, smoking was associated with 0.08% 173 
higher HbA1c compared to no smoking, which is equal to 0.25 times the SD. As expected, 174 
vegetable intake had the opposite effect being associated with lower age-sex adjusted HbA1c levels 175 
with more portions consumed. In fact, for every extra 80g portion of vegetable consumed there was 176 
an associated 0.01% reduction in HbA1c.  177 
The hypothesis that glycative and oxidative damage are closely related in vivo is supported by 178 
evidence showing that in purified plasma albumin, oxidative damage - measured as a reduction in 179 
free thiol groups - was positively related to glycative damage, measured as fructosamine and 180 
carbonyl rate(88). Moreover, Cys-34, a key site of oxidative damage in albumin in vivo(89), has also 181 
been suggested as a glycation site, especially from a-oxoaldehydes(90). Since in-vitro models are 182 
often removed from physiologically-relevant reactions, it is important to setup mechanistic studies 183 
with adequate parameters. To test the hypothesis that, in normoglycaemia, oxidative stress promotes 184 
glycation, we carried out 4-week long albumin incubation studies (albumin has a half-life of 14-28 185 
days). Glucose concentrations of 5 and 10 mM were employed to replicate normoglycaemia and 186 
(non-controlled) diabetes, respectively, while 20 mM and 30 mM glucose were used as positive 187 
controls (supraphysiological concentrations). There is no consensus on the plasma levels of 188 
hydrogen peroxide (from nearly 0 to 35 μM(91-93)), we used a low concentration of hydrogen 189 
peroxide (H2O2, 10 nM) to simulate physiologically relevant oxidative stress (94). Co-incubation of 190 
albumin with glucose and physiological levels of H2O2 led to significantly higher glycation at all 191 
glucose levels tested, after 2 weeks and 4 weeks incubation, compared to glucose alone. At 192 
physiological glucose level (5mM), there was no significant glycation (versus negative control) in 193 
absence of H2O2 (Figure 2), indicating that oxidative stress plays an important in glycation in 194 
normoglycaemia. Physiologically, in the presence of oxidative stress, proteins can get quickly 195 
oxidised and remain in this form in circulation until they are degraded by proteases(95). As 196 
extracellular/circulating proteins are more likely to get oxidised first before getting glycated, due to 197 
the relative speed of the reactions, the same experiments were repeated using pre-oxidised protein. 198 
The pre-oxidised BSA led to a higher production of fructosamine when incubated with glucose as 199 
compared to the native incubated BSA.  Oxidative stress also drove glycation of human plasma 200 
proteins, in presence of 5 mM glucose.  201 
Brought together, these results(85; 96) indicate the potential role for oxidative stress as a driver for 202 
glycation in normoglycaemic individuals. The increased levels of HbA1c seen in smokers and those 203 
consuming low amounts of fruit and vegetables could be partially due to their impaired redox status, 204 
as stipulated by the epidemiological data. This interaction between oxidative stress and glycation 205 
will be subtle but with potentially sizeable long term effects. Hence, dietary interventions aiming to 206 
restore the antioxidant/pro-oxidant balance in subjects at high risk of oxidative stress could be of 207 
value in chronic disease prevention.  208 
 209 
Antiglycative capacity of antioxidants and polyphenols 210 
In the search for compounds able to inhibit or slow the glycation reaction, antioxidants have 211 
attracted attention. The first AGE blocker identified is aminoguanidine(97); a dicarbonyl scavenging 212 
agent that reduces AGE production by removing the oxidatively produced precursors, like a-213 
oxoaldehydes(98; 99).  Aminoguanidine, like other glycation inhibiting compounds aspirin and 214 
ibuprofen, has the capacity to scavenge free radicals and improve redox status, which may 215 
contribute to their antiglycative capacity(99-101).  216 
The antiglycative capacity of antioxidant vitamins and polyphenols has also been investigated, with 217 
in-vitro studies showing some polyphenols and phenolic acids to be even more effective than 218 
aminoguanidine in inhibiting glycation(102-104). Herb extracts and commonly consumed herbal 219 
preparations have been shown to inhibit glycation of albumin in experimental settings. Red wine, 220 
green tea, maté tea (Ilex paraguariensis)(105; 106), cinnamon, garlic(107) and other herbs used to 221 
prepare hot drinks or added during cooking are rich in a variety of micronutrients with anti-222 
glycative effects(108; 109).  A recent review of the literature by Xie et al.(110) analysed results from 19 223 
in-vitro trials and 11 animal studies and concluded that antiglycative capacity of polyphenols is 224 
linked to ring hydroxylation patterns. In this context, molecules with hydroxyl groups in the A and 225 
B rings (i.e. apigenin < luteolin, fisetin < quercetin, daidzein < genistein) those with multiple 226 
hydroxyl groups especially in the ortho- and meta- structure (i.e. phloridzin < sieboldin ), the 227 
proanthocyanidin di/trimmers and the ellagitannins all showed increased antiglycative capacity. On 228 
the other hand, hydrogenation of the C2-C3 bond (i.e. eriodictyol < luteolin), methylation (i.e. 229 
diosmetin < luteolin) and the addition of rutinosides all decreased the antiglycative capacity(110). 230 
The results of in-vitro studies are still heterogeneous and a thorough review of the glycation models 231 
and assays used would help to understand why translation of the findings to a physiological setting 232 
has not been forthcoming. Some of the reasons include use of high glucose or fructose 233 
concentrations, supraphysiological concentrations of polyphenols/phenolic acids, use of compounds 234 
with very limited bioavailabilty, and variability in the incubation period/temperature. Doses tested 235 
in vitro are, most of the times beyond concentration that could be reached via habitual consumption 236 
of phenolic-rich foodstuff. Most polyphenols are metabolised extensively in the gut and by the liver 237 
after ingestion, and have generally a low bioavailability(111; 112). Therefore studies focusing on the 238 
systemic effects of the “parent” compounds, as found in foods, are likely to have low translational 239 
values. Phenolic acids, such as 3-hydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid and 240 
caffeic acid, on the other hand, are formed after exposure to the gut microbiota, have a higher 241 
bioavailability than larger polyphenols and are more likely to exert systemic effects(111; 112).  242 
 Despite the extensive mechanistic evidence, epidemiological data on polyphenol consumption are 243 
scarce. Principal reasons include the difficulties and the biases associated with deriving polyphenol 244 
intake data from dietary records. The process involves the use of databases, such as 245 
PhenolExplorer(113)  documenting the polyphenol content of foods(113; 114) and/or the analysis of 246 
Food Frequency Questionnaires to identify patterns of higher intake of polyphenol-rich foods. So 247 
far, there are no reports addressing the relationship between polyphenol intake and glycation levels. 248 
The reports associating polyphenol intake with diabetes risk have so far reached contradictory 249 
conclusions(115-117). Our own systematic review of the literature relating antioxidant intake with 250 
protein glycation in normoglycaemia showed that human trials with polyphenol rich supplements 251 
and foods are few and characterised by high heterogeneity, poor design and small samples size (in 252 
preparation). In the past 20 years, only 14 trials used polyphenols as a mean to reduce glycation in 253 
non-diabetic individuals, out of which two did not have any control group(118; 119). Taken together, 254 
the results of these studies seem to suggest that polyphenol supplementation fails to improve 255 
glycation markers in non-diabetic individuals, although this conclusion is most likely to be a result 256 
of poor study design.  In populations with established IGT, increased intake of polyphenols might 257 
be promising in reducing protein glycation(120; 121), but no hard conclusions can be made at this point.  258 
The bioactive molecules tested were diverse with no standardisation in dose. The majority of the 259 
studies had glycation as a secondary outcome, leading to low statistical power, and did not have 260 
sufficient duration to detect changes, if any were present.  261 
Considerations for the future 262 
Although the importance of glycation as a marker of disease pathogenesis outside of diabetes is 263 
becoming clearer, it is yet to be fully understood. More studies are required to describe the 264 
interactions between oxidative stress and glycation, especially in normoglycaemia. The importance 265 
of RAGE activation to signal intracellular events that promote dysfunction and the factors that 266 
determine the levels of sRAGE have not attracted the required attention.   267 
As far as polyphenol and antioxidant trials are concerned, there is still much improvement to be 268 
done in terms of study design before conclusions can be reached. If the working hypothesis is that 269 
polyphenols will exert health benefits via their antioxidant capacity, then markers to document such 270 
improvements should be included and results on glycation markers, like HbA1c, should be 271 
discussed alongside oxidative stress improvements.  272 
Sample size and targeting the correct population are two key aspect of study design to be considered. 273 
Polyphenol supplementation in a relatively healthy population is likely to have a subtle effect on 274 
health markers and hence studies with large sample sizes are likely to be required(122). The majority 275 
of the studies to-date fall short of that sample size and are hence likely to be underpowered. As a 276 
result, we should be careful in concluding that polyphenol supplementation has no effect on 277 
glycation. The current literature may be just describing a lack of power to detect such an effect if 278 
any.  279 
A good understanding of the supplement used, with data on bioavailability, composition and dose 280 
would allow for a more effective comparison of the studies. Also ensuring that the study duration is 281 
sufficient to detect changes in glycation markers is a vital improvement. Albumin has a half-life of 282 
14-28 days while hemoglobin’s half-life is 90 days; studies with duration shorter than the half-life 283 
of the target protein are unlikely to detect any changes in protein glycation. Also even though 284 
physical protein damage is the main pathway of glycation-related pathogenesis; RAGE activation, 285 
sRAGE levels and glycation related inflammation are also important pathways for the involvement 286 
of glycation in disease pathogenesis, but are so far understudied(123; 124).  287 
 288 
Conclusion 289 
Glycation is an important mechanism of end organ damage and disease pathogenesis affecting 290 
individuals throughout the lifecourse. With many target molecules and mechanisms of actions 291 
glycation and oxidative stress are increasingly recognised as of clinical importance not only in 292 
diabetes but in normoglycaemia as well. Epidemiological and in-vitro data so far are supporting the 293 
hypothesis that oxidative stress and its regulation with antioxidants is of importance in an attempt to 294 
inhibit glycation, especially in normoglycaemia. Although the importance of nutrition in glycation 295 
regulation is becoming more apparent, clinical trials with polyphenols so far lack the quality to form 296 
conclusive decisions. More large scale and high quality interventions are needed before 297 
recommendations can be made.  298 
Acknowledgements 299 
The authors have no conflicts of interest to declare. AV is in receipt of a scholarship from Yorkhill 300 
Children’s Foundation.  AV conducted the studies described and drafted the manuscript. EC and 301 
MEJL secured the funding, supervised the studies and contributed to the drafting of the manuscript. 302 
 303 
References 304 
1. Maillard L (1912) Action des acides amines sur les sucres: Formation des melanoidines par voie 305 
methodologique. Comptes Rendus de l’Academie des Sciences 156, 148-149. 306 
2. Hodge JE (1955) The Amadori rearrangement. Advances in carbohydrate chemistry 10, 169-205. 307 
3. Koenig RJ, Peterson CM, Jones RL et al. (1976) Correlation of glucose regulation and hemoglobin AIc in 308 
diabetes mellitus. The New England journal of medicine 295, 417-420. 309 
4. Koenig RJ, Peterson CM, Kilo C et al. (1976) Hemoglobin AIc as an indicator of the degree of glucose 310 
intolerance in diabetes. Diabetes 25, 230-232. 311 
5. Koenig RJ, Blobstein SH, Cerami A (1977) Structure of carbohydrate of hemoglobin AIc. The Journal of 312 
biological chemistry 252, 2992-2997. 313 
6. Schmidt AM, Hori O, Brett J et al. (1994) Cellular receptors for advanced glycation end products. 314 
Implications for induction of oxidant stress and cellular dysfunction in the pathogenesis of vascular lesions. 315 
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association 14, 1521-1528. 316 
7. Sell DR, Monnier VM (1989) Isolation, purification and partial characterization of novel fluorophores from 317 
aging human insoluble collagen-rich tissue. Connective tissue research 19, 77-92. 318 
8. Monami M, Lamanna C, Lambertucci L et al. (2006) Fasting and post-prandial glycemia and their 319 
correlation with glycated hemoglobin in type 2 diabetes. J Endocrinol Invest 29, 619-624. 320 
9. Landgraf R (2004) The relationship of postprandial glucose to HbA1c. Diabetes/Metabolism Research and 321 
Reviews 20, S9-S12. 322 
10. Ahmed N, Babaei-Jadidi R, Howell SK et al. (2005) Glycated and Oxidized Protein Degradation Products 323 
Are Indicators of Fasting and Postprandial Hyperglycemia in Diabetes. Diabetes Care 28, 2465-2471. 324 
11. Beisswenger PJ, Howell SK, O’Dell RM et al. (2001) α-Dicarbonyls Increase in the Postprandial Period 325 
and Reflect the Degree of Hyperglycemia. Diabetes Care 24, 726-732. 326 
12. Brownlee M, Cerami A, Vlassara H (1988) Advanced Products of Nonenzymatic Glycosylation and the 327 
Pathogenesis of Diabetic Vascular-Disease. Diabetes Metab Rev 4, 437-451. 328 
13. Lepape A, Guitton JD, Muh JP (1981) Modifications of Glomerular Basement-Membrane Cross-Links in 329 
Experimental Diabetic Rats. Biochem Bioph Res Co 100, 1214-1221. 330 
14. Sensi M, Tanzi P, Bruno MR et al. (1986) Human Glomerular-Basement-Membrane - Altered Binding 331 
Characteristics Following Invitro Nonenzymatic Glycosylation. Annals of the New York Academy of Sciences 332 
488, 549-552. 333 
15. Vlassara H (1996) Advanced glycation end-products and atherosclerosis. Annals of medicine 28, 419-426. 334 
16. Sell DR, Monnier VM (1989) Structure elucidation of a senescence cross-link from human extracellular 335 
matrix. Implication of pentoses in the aging process. The Journal of biological chemistry 264, 21597-21602. 336 
17. Monnier VM (1989) Toward a Maillard reaction theory of aging. Progress in clinical and biological 337 
research 304, 1-22. 338 
18. Bobbink IW, de Boer HC, Tekelenburg WL et al. (1997) Effect of extracellular matrix glycation on 339 
endothelial cell adhesion and spreading: involvement of vitronectin. Diabetes 46, 87-93. 340 
19. Kent MJ, Light ND, Bailey AJ (1985) Evidence for glucose-mediated covalent cross-linking of collagen 341 
after glycosylation in vitro. The Biochemical journal 225, 745-752. 342 
20. Tanaka S, Avigad G, Brodsky B et al. (1988) Glycation induces expansion of the molecular packing of 343 
collagen. Journal of molecular biology 203, 495-505. 344 
21. Sensi M, Tanzi P, Bruno MR et al. (1989) Nonenzymic glycation of isolated human glomerular basement 345 
membrane changes its physicochemical characteristics and binding properties. Nephron 52, 222-226. 346 
22. Klein RL, Laimins M, Lopes-Virella MF (1995) Isolation, characterization, and metabolism of the glycated 347 
and nonglycated subfractions of low-density lipoproteins isolated from type I diabetic patients and 348 
nondiabetic subjects. Diabetes 44, 1093-1098. 349 
23. Iwashima Y, Eto M, Hata A et al. (2000) Advanced glycation end products-induced gene expression of 350 
scavenger receptors in cultured human monocyte-derived macrophages. Biochem Bioph Res Co 277, 368-351 
380. 352 
24. Basta G, Schmidt AM, De Caterina R (2004) Advanced glycation end products and vascular inflammation: 353 
implications for accelerated atherosclerosis in diabetes. Cardiovascular research 63, 582-592. 354 
25. Schmidt AM, Vianna M, Gerlach M et al. (1992) Isolation and characterization of two binding proteins 355 
for advanced glycosylation end products from bovine lung which are present on the endothelial cell surface. 356 
The Journal of biological chemistry 267, 14987-14997. 357 
26. Vlassara H, Li YM, Imani F et al. (1995) Identification of galectin-3 as a high-affinity binding protein for 358 
advanced glycation end products (AGE): a new member of the AGE-receptor complex. Molecular medicine 1, 359 
634-646. 360 
27. Schmidt AM, Hori O, Chen JX et al. (1995) Advanced glycation endproducts interacting with their 361 
endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human 362 
endothelial cells and in mice. A potential mechanism for the accelerated vasculopathy of diabetes. The 363 
Journal of clinical investigation 96, 1395-1403. 364 
28. Hofmann MA, Drury S, Fu CF et al. (1999) RAGE mediates a novel proinflammatory axis: A central cell 365 
surface receptor for S100/calgranulin polypeptides. Cell 97, 889-901. 366 
29. Kislinger T, Fu CF, Huber B et al. (1999) N-epsilon-(carboxymethyl)lysine adducts of proteins are ligands 367 
for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene 368 
expression. Journal of Biological Chemistry 274, 31740-31749. 369 
30. Takeuchi M, Yamagishi S (2008) Possible involvement of advanced glycation end-products (AGEs) in the 370 
pathogenesis of Alzheimer's disease. Current pharmaceutical design 14, 973-978. 371 
31. Munch G, Westcott B, Menini T et al. (2012) Advanced glycation endproducts and their pathogenic roles 372 
in neurological disorders. Amino Acids 42, 1221-1236. 373 
32. Zhang QB, Ames JM, Smith RD et al. (2009) A Perspective on the Maillard Reaction and the Analysis of 374 
Protein Glycation by Mass Spectrometry: Probing the Pathogenesis of Chronic Disease. J Proteome Res 8, 375 
754-769. 376 
33. Stitt AW (2001) Advanced glycation: an important pathological event in diabetic and age related ocular 377 
disease. British Journal of Ophthalmology 85, 746-753. 378 
34. Creager MA, Lüscher TF, of pwta et al. (2003) Diabetes and Vascular Disease: Pathophysiology, Clinical 379 
Consequences, and Medical Therapy: Part I. Circulation 108, 1527-1532. 380 
35. Mallidis C, Agbaje IM, Rogers DA et al. (2009) Advanced glycation end products accumulate in the 381 
reproductive tract of men with diabetes. International journal of andrology 32, 295-305. 382 
36. Diamanti-Kandarakis E, Piperi C, Patsouris E et al. (2007) Immunohistochemical localization of advanced 383 
glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochemistry 384 
and cell biology 127, 581-589. 385 
37. Mallidis C, Agbaje I, Rogers D et al. (2007) Distribution of the receptor for advanced glycation end 386 
products in the human male reproductive tract: prevalence in men with diabetes mellitus. Human 387 
reproduction 22, 2169-2177. 388 
38. Karimi J, Goodarzi MT, Tavilani H et al. (2012) Increased receptor for advanced glycation end products 389 
in spermatozoa of diabetic men and its association with sperm nuclear DNA fragmentation. Andrologia 44 390 
Suppl 1, 280-286. 391 
39. Bonetti TC, Borges E, Jr., Braga DP et al. (2013) Intrafollicular soluble receptor for advanced glycation 392 
end products (sRAGE) and embryo quality in assisted reproduction. Reproductive biomedicine online 26, 62-393 
67. 394 
40. Malickova K, Jarosova R, Rezabek K et al. (2010) Concentrations of sRAGE in serum and follicular fluid in 395 
assisted reproductive cycles--a preliminary study. Clinical laboratory 56, 377-384. 396 
41. Jinno M, Takeuchi M, Watanabe A et al. (2011) Advanced glycation end-products accumulation 397 
compromises embryonic development and achievement of pregnancy by assisted reproductive technology. 398 
Human reproduction 26, 604-610. 399 
42. Hao L, Noguchi S, Kamada Y et al. (2008) Adverse effects of advanced glycation end products on 400 
embryonal development. Acta medica Okayama 62, 93-99. 401 
43. Oliver EA, Buhimschi CS, Dulay AT et al. (2011) Activation of the receptor for advanced glycation end 402 
products system in women with severe preeclampsia. The Journal of clinical endocrinology and metabolism 403 
96, 689-698. 404 
44. Naruse K, Sado T, Noguchi T et al. (2012) Peripheral RAGE (receptor for advanced glycation 405 
endproducts)-ligands in normal pregnancy and preeclampsia: novel markers of inflammatory response. 406 
Journal of reproductive immunology 93, 69-74. 407 
45. Cooke CL, Brockelsby JC, Baker PN et al. (2003) The receptor for advanced glycation end products (RAGE) 408 
is elevated in women with preeclampsia. Hypertension in pregnancy : official journal of the International 409 
Society for the Study of Hypertension in Pregnancy 22, 173-184. 410 
46. Fineschi S, De Cunto G, Facchinetti F et al. (2013) Receptor for advanced glycation end products 411 
contributes to postnatal pulmonary development and adult lung maintenance program in mice. American 412 
journal of respiratory cell and molecular biology 48, 164-171. 413 
47. Gul A, Rahman MA, Salim A et al. (2009) Advanced glycation end products in senile diabetic and 414 
nondiabetic patients with cataract. Journal of diabetes and its complications 23, 343-348. 415 
48. Gkogkolou P, Bohm M (2012) Advanced glycation end products: Key players in skin aging? Dermato-416 
endocrinology 4, 259-270. 417 
49. Cai W, He JC, Zhu L et al. (2007) Reduced oxidant stress and extended lifespan in mice exposed to a low 418 
glycotoxin diet: association with increased AGER1 expression. The American journal of pathology 170, 1893-419 
1902. 420 
50. Taylor A, Lipman RD, Jahngen-Hodge J et al. (1995) Dietary calorie restriction in the Emory mouse: 421 
effects on lifespan, eye lens cataract prevalence and progression, levels of ascorbate, glutathione, glucose, 422 
and glycohemoglobin, tail collagen breaktime, DNA and RNA oxidation, skin integrity, fecundity, and cancer. 423 
Mechanisms of ageing and development 79, 33-57. 424 
51. Reiser KM (1994) Influence of Age and Long-Term Dietary Restriction on Enzymatically Mediated 425 
Crosslinks and Nonenzymatic Glycation of Collagen in Mice. Journal of Gerontology 49, B71-B79. 426 
52. Mouton PR, Chachich ME, Quigley C et al. (2009) Caloric restriction attenuates amyloid deposition in 427 
middle-aged dtg APP/PS1 mice. Neuroscience letters 464, 184-187. 428 
53. Cai W, He JC, Zhu L et al. (2008) Oral glycotoxins determine the effects of calorie restriction on oxidant 429 
stress, age-related diseases, and lifespan. The American journal of pathology 173, 327-336. 430 
54. Stensen MH, Tanbo T, Storeng R et al. (2014) Advanced glycation end products and their receptor 431 
contribute to ovarian ageing. Human reproduction 29, 125-134. 432 
55. Smith MA, Sayre LM, Monnier VM et al. (1995) Radical AGEing in Alzheimer's disease. Trends in 433 
neurosciences 18, 172-176. 434 
56. Srikanth V, Maczurek A, Phan T et al. (2011) Advanced glycation endproducts and their receptor RAGE 435 
in Alzheimer's disease. Neurobiology of aging 32, 763-777. 436 
57. Vitek MP, Bhattacharya K, Glendening JM et al. (1994) Advanced glycation end products contribute to 437 
amyloidosis in Alzheimer disease. Proceedings of the National Academy of Sciences of the United States of 438 
America 91, 4766-4770. 439 
58. Bailey AJ, Sims TJ, Avery NC et al. (1993) Chemistry of collagen cross-links: glucose-mediated covalent 440 
cross-linking of type-IV collagen in lens capsules. The Biochemical journal 296 ( Pt 2), 489-496. 441 
59. Nicholl ID, Stitt AW, Moore JE et al. (1998) Increased levels of advanced glycation endproducts in the 442 
lenses and blood vessels of cigarette smokers. Molecular medicine 4, 594-601. 443 
60. American Diabetes A, European Association for the Study of D, International Federation of Clinical C et 444 
al. (2007) Consensus statement on the worldwide standardisation of the HbA1c measurement. 445 
Diabetologia 50, 2042-2043. 446 
61. American Diabetes A (2011) Diagnosis and classification of diabetes mellitus. Diabetes Care 34 Suppl 1, 447 
S62-69. 448 
62. Porta M, Sjoelie AK, Chaturvedi N et al. (2001) Risk factors for progression to proliferative diabetic 449 
retinopathy in the EURODIAB Prospective Complications Study. Diabetologia 44, 2203-2209. 450 
63. Klein R, Klein BE, Moss SE et al. (1994) The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. 451 
Ten-year incidence and progression of diabetic retinopathy. Archives of ophthalmology 112, 1217-1228. 452 
64. Klein R, Klein BE, Moss SE et al. (1998) The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. 453 
The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. 454 
Ophthalmology 105, 1801-1815. 455 
65. Anonymous (1995) The relationship of glycemic exposure (HbA1c) to the risk of development and 456 
progression of retinopathy in the diabetes control and complications trial. Diabetes 44, 968-983. 457 
66. McCarter RJ, Hempe JM, Gomez R et al. (2004) Biological variation in HbA1c predicts risk of retinopathy 458 
and nephropathy in type 1 diabetes. Diabetes Care 27, 1259-1264. 459 
67. El-Salem K, Ammari F, Khader Y et al. (2007) Elevated glycosylated hemoglobin is associated with 460 
subclinical neuropathy in neurologically asymptomatic type-2 diabetic patients: A prospective study. Eur J 461 
Neurol 14, 251-251. 462 
68. Khaw KT, Wareham N, Bingham S et al. (2004) Association of hemoglobin A1c with cardiovascular 463 
disease and mortality in adults: the European prospective investigation into cancer in Norfolk. Annals of 464 
internal medicine 141, 413-420. 465 
69. Khaw KT, Wareham N, Bingham S et al. (2004) Preliminary communication: glycated hemoglobin, 466 
diabetes, and incident colorectal cancer in men and women: a prospective analysis from the European 467 
prospective investigation into cancer-Norfolk study. Cancer epidemiology, biomarkers & prevention : a 468 
publication of the American Association for Cancer Research, cosponsored by the American Society of 469 
Preventive Oncology 13, 915-919. 470 
70. Selvin E, Steffes MW, Zhu H et al. (2010) Glycated hemoglobin, diabetes, and cardiovascular risk in 471 
nondiabetic adults. The New England journal of medicine 362, 800-811. 472 
71. Selvin E, Coresh J, Shahar E et al. (2005) Glycaemia (haemoglobin A1c) and incident ischaemic stroke: 473 
the Atherosclerosis Risk in Communities (ARIC) Study. Lancet neurology 4, 821-826. 474 
72. Matsushita K, Blecker S, Pazin A et al. (2010) The Association of Hemoglobin A1c With Incident Heart 475 
Failure Among People Without Diabetes: The Atherosclerosis Risk in Communities Study. Diabetes 59, 476 
2020-2026. 477 
73. Selvin E, Rawlings AM, Grams M et al. (2014) Fructosamine and glycated albumin for risk stratification 478 
and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the 479 
Atherosclerosis Risk in Communities (ARIC) study. The Lancet Diabetes & Endocrinology. 480 
74. Barr EL, Boyko EJ, Zimmet PZ et al. (2009) Continuous relationships between non-diabetic 481 
hyperglycaemia and both cardiovascular disease and all-cause mortality: the Australian Diabetes, Obesity, 482 
and Lifestyle (AusDiab) study. Diabetologia 52, 415-424. 483 
75. de Vegt F, Dekker JM, Ruhe HG et al. (1999) Hyperglycaemia is associated with all-cause and 484 
cardiovascular mortality in the Hoorn population: the Hoorn Study. Diabetologia 42, 926-931. 485 
76. van't Riet E, Rijkelijkhuizen JM, Alssema M et al. (2012) HbA1c is an independent predictor of non-fatal 486 
cardiovascular disease in a Caucasian population without diabetes: a 10-year follow-up of the Hoorn Study. 487 
Eur J Prev Cardiol 19, 23-31. 488 
77. Meigs JB, Nathan DM, D'Agostino RB et al. (2002) Fasting and postchallenge glycemia and 489 
cardiovascular disease risk - The framingham offspring study. Diabetes Care 25, 1845-1850. 490 
78. Park S, BarrettConnor E, Wingard DL et al. (1996) GHb is a better predictor at cardiovascular disease 491 
than fasting or postchallenge plasma glucose in women without diabetes - The Rancho Bernardo Study. 492 
Diabetes Care 19, 450-456. 493 
79. Pradhan AD, Rifai N, Buring JE et al. (2007) Hemoglobin a1c predicts diabetes but not cardiovascular 494 
disease in nondiabetic women. Am J Med 120, 720-727. 495 
80. Lin J, Ridker PM, Rifai N et al. (2006) A prospective study of hemoglobin A1c concentrations and risk of 496 
breast cancer in women. Cancer Res 66, 2869-2875. 497 
81. Blake GJ, Pradhan AD, Manson JE et al. (2004) Hemoglobin A(1c) level and future cardiovascular events 498 
among women. Arch Intern Med 164, 757-761. 499 
82. Sakurai M, Saitoh S, Miura K et al. (2013) HbA1c and the risks for all-cause and cardiovascular mortality 500 
in the general Japanese population: NIPPON DATA90. Diabetes Care 36, 3759-3765. 501 
83. Edwards BK, Ward E, Kohler BA et al. (2010) Annual report to the nation on the status of cancer, 1975-502 
2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) 503 
to reduce future rates. Cancer 116, 544-573. 504 
84. McPherson K, Steel CM, Dixon JM (2000) ABC of breast diseases. Breast cancer-epidemiology, risk 505 
factors, and genetics. BMJ 321, 624-628. 506 
85. Vlassopoulos A, Lean M, Combet E (2013) Influence of smoking and diet on glycated haemoglobin and 507 
'pre-diabetes' categorisation: a cross-sectional analysis. BMC Public Health 13, 1013. 508 
86. Sargeant LA, Khaw K-T, Bingham S et al. (2001) Cigarette smoking and glycaemia: the EPIC-Norfolk Study. 509 
International Journal of Epidemiology 30, 547-554. 510 
87. Clair C, Bitton A, Meigs JB et al. (2011) Relationships of Cotinine and Self-Reported Cigarette Smoking 511 
With Hemoglobin A1c in the U.S.: Results from the National Health and Nutrition Examination Survey, 512 
1999–2008. Diabetes care 34, 2250-2255. 513 
88. Guerin-Dubourg A, Catan A, Bourdon E et al. (2012) Structural modifications of human albumin in 514 
diabetes. Diabetes & metabolism 38, 171-178. 515 
89. Kawakami A, Kubota K, Yamada N et al. (2006) Identification and characterization of oxidized human 516 
serum albumin. FEBS Journal 273, 3346-3357. 517 
90. Rondeau P, Bourdon E (2011) The glycation of albumin: structural and functional impacts. Biochimie 93, 518 
645-658. 519 
91. Varma SD, Devamanoharan PS (1991) Hydrogen peroxide in human blood. Free Radic Res Commun 14, 520 
125-131. 521 
92. Lacy F, O'Connor DT, Schmid-Schönbein GW (1998) Plasma hydrogen peroxide production in 522 
hypertensives and normotensive subjects at genetic risk of hypertension. Journal of hypertension 16, 291-523 
303. 524 
93. Frei B, Yamamoto Y, Niclas D et al. (1988) Evaluation of an isoluminol chemiluminescence assay for the 525 
detection of hydroperoxides in human blood plasma. Analytical Biochemistry 175, 120-130. 526 
94. Mueller S, Riedel H-D, Stremmel W (1997) Determination of Catalase Activity at Physiological Hydrogen 527 
Peroxide Concentrations. Analytical Biochemistry 245, 55-60. 528 
95. Stadtman ER, Levine RL (2000) Protein oxidation. Ann N Y Acad Sci 899, 191-208. 529 
96. Vlassopoulos A, Lean ME, Combet E (2013) Role of oxidative stress in physiological albumin glycation: a 530 
neglected interaction. Free radical biology & medicine 60, 318-324. 531 
97. Brownlee M, Vlassara H, Kooney A et al. (1986) Aminoguanidine prevents diabetes-induced arterial wall 532 
protein cross-linking. Science 232, 1629-1632. 533 
98. Ahmed N, Thornalley PJ (2002) Chromatographic assay of glycation adducts in human serum albumin 534 
glycated in vitro by derivatization with 6-aminoquinolyl-N-hydroxysuccinimidyl-carbamate and intrinsic 535 
fluorescence. The Biochemical journal 364, 15-24. 536 
99. Thornalley PJ (2003) Use of aminoguanidine (Pimagedine) to prevent the formation of advanced 537 
glycation endproducts. Arch Biochem Biophys 419, 31-40. 538 
100. Urios P, Grigorova-Borsos AM, Sternberg M (2007) Aspirin inhibits the formation of pentosidine, a 539 
cross-linking advanced glycation end product, in collagen. Diabetes research and clinical practice 77, 337-540 
340. 541 
101. Menzel EJ, Reihsner R (1996) Comparison of the effect of different inhibitors of the non-enzymatic 542 
glycation of rat tail tendons and bovine serum albumin. Annals of clinical biochemistry 33 ( Pt 3), 241-248. 543 
102. Wu JW, Hsieh CL, Wang HY et al. (2009) Inhibitory effects of guava (Psidium guajava L.) leaf extracts 544 
and its active compounds on the glycation process of protein. Food Chem 113, 78-84. 545 
103. Choi SY, Jung SH, Lee HS et al. (2008) Glycation inhibitory activity and the identification of an active 546 
compound in Plantago asiatica extract. Phytother Res 22, 323-329. 547 
104. Kiho T, Usui S, Hirano K et al. (2004) Tomato paste fraction inhibiting the formation of advanced 548 
glycation end-products. Bioscience, biotechnology, and biochemistry 68, 200-205. 549 
105. Gugliucci A, Bastos DH, Schulze J et al. (2009) Caffeic and chlorogenic acids in Ilex paraguariensis 550 
extracts are the main inhibitors of AGE generation by methylglyoxal in model proteins. Fitoterapia 80, 339-551 
344. 552 
106. Bixby M, Spieler L, Menini T et al. (2005) Ilex paraguariensis extracts are potent inhibitors of 553 
nitrosative stress: a comparative study with green tea and wines using a protein nitration model and 554 
mammalian cell cytotoxicity. Life Sci 77, 345-358. 555 
107. Ahmad MS, Pischetsrieder M, Ahmed N (2007) Aged garlic extract and S-allyl cysteine prevent 556 
formation of advanced glycation endproducts. Eur J Pharmacol 561, 32-38. 557 
108. Xi M, Hai C, Tang H et al. (2008) Antioxidant and antiglycation properties of total saponins extracted 558 
from traditional Chinese medicine used to treat diabetes mellitus. Phytother Res 22, 228-237. 559 
109. Stote KS, Baer DJ (2008) Tea consumption may improve biomarkers of insulin sensitivity and risk 560 
factors for diabetes. J Nutr 138, 1584S-1588S. 561 
110. Xie Y, Chen X (2013) Structures required of polyphenols for inhibiting advanced glycation end products 562 
formation. Current drug metabolism 14, 414-431. 563 
111. Crozier A, Jaganath IB, Clifford MN (2009) Dietary phenolics: chemistry, bioavailability and effects on 564 
health. Natural product reports 26, 1001-1043. 565 
112. Del Rio D, Costa LG, Lean ME et al. (2010) Polyphenols and health: what compounds are involved? 566 
Nutr Metab Cardiovasc Dis 20, 1-6. 567 
113. Rothwell JA, Urpi-Sarda M, Boto-Ordonez M et al. (2012) Phenol-Explorer 2.0: a major update of the 568 
Phenol-Explorer database integrating data on polyphenol metabolism and pharmacokinetics in humans and 569 
experimental animals. Database : the journal of biological databases and curation 2012, bas031. 570 
114. Bhagwat SA, Haytowitz, D.B., Holden, J.M. (2013) USDA database for the flavonoid content of selected 571 
foods, Release 3.1. USA: USDA. 572 
115. Nettleton JA, Harnack LJ, Scrafford CG et al. (2006) Dietary flavonoids and flavonoid-rich foods are not 573 
associated with risk of type 2 diabetes in postmenopausal women. J Nutr 136, 3039-3045. 574 
116. Wedick NM, Pan A, Cassidy A et al. (2012) Dietary flavonoid intakes and risk of type 2 diabetes in US 575 
men and women. Am J Clin Nutr 95, 925-933. 576 
117. Song Y, Manson JE, Buring JE et al. (2005) Associations of dietary flavonoids with risk of type 2 577 
diabetes, and markers of insulin resistance and systemic inflammation in women: a prospective study and 578 
cross-sectional analysis. Journal of the American College of Nutrition 24, 376-384. 579 
118. Basu A, Newman ED, Bryant AL et al. (2013) Pomegranate polyphenols lower lipid peroxidation in 580 
adults with type 2 diabetes but have no effects in healthy volunteers: a pilot study. Journal of nutrition and 581 
metabolism 2013, 708381. 582 
119. Celec P, Hodosy J, Palffy R et al. (2013) The short-term effects of soybean intake on oxidative and 583 
carbonyl stress in men and women. Molecules 18, 5190-5200. 584 
120. Cho Y-Y, Baek N-I, Chung H-G et al. (2012) Randomized controlled trial of Sajabalssuk (Artemisia 585 
princeps Pampanini) to treat pre-diabetes. European Journal of Integrative Medicine 4, e299-e308. 586 
121. Fukino Y, Ikeda A, Maruyama K et al. (2008) Randomized controlled trial for an effect of green tea-587 
extract powder supplementation on glucose abnormalities. European journal of clinical nutrition 62, 953-588 
960. 589 
122. Cicero AFG, Nascetti S, Lopez-Sabater MC et al. (2008) Changes in LDL fatty acid composition as a 590 
response to olive oil treatment are inversely related to lipid oxidative damage: The EUROLIVE study. Journal 591 
of the American College of Nutrition 27, 314-320. 592 
123. McNair ED, Wells CR, Qureshi M et al. (2010) Soluble Receptors for Advanced Glycation End Products 593 
(sRAGE) as a Predictor of Restenosis Following Percutaneous Coronary Intervention. Clin Cardiol 33, 678-594 
685. 595 
124. Ng ZX, Chua KH, Iqbal T et al. (2013) Soluble Receptor for Advanced Glycation End-Product 596 
(sRAGE)/Pentosidine Ratio: A Potential Risk Factor Determinant for Type 2 Diabetic Retinopathy. Int J Mol 597 
Sci 14, 7480-7491. 598 
 599 
600 
 601 
Figure1. Age-sex adjusted mean (SD) of %HbA1c according to number of cigarettes/day 602 
 603 
Figure as presented in Vlassopoulos et at 2013(85) 604 
Figure 2. Differences in fructosamine concentration after incubation with glucose alone compared to glucose and 605 
constant exposure to oxidation from hydrogen peroxide (10 nM) after two and four weeks incubation.   606 
 607 
*p<0.05 native vs. constant oxidation ; fructosamine was measured using the nitroblue tetrazolium method with the 608 
synthetic fructosamine equivalent deoxy-morpholino-fructose (DMF) as a calibrator 609 
Adapted from Vlassopoulos et al (2013)(96) 610 
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